For generations, medicine held that activating the immune system's interferon signals was a straightforward ally against cancer — more activation, more protection. New research by Gerald Shadel, Melissa Johnson, and colleagues now reveals that when interferon exposure becomes chronic, the immune system can paradoxically turn against itself, creating conditions that shelter tumors rather than destroy them. The discovery, rooted in the unexpected behavior of mitochondrial RNA, invites a fundamental rethinking of how we wield the body's own defenses — not as a volume to be turned up, but as a bal
Chronic Interferon Paradox: How Immune Signaling Can Fuel Tumor Growth
Cobertura Relacionada
Two leading scientists have quit Lucy Letby's defence team citing concerns about the scientific credibility of some argu…
News-Medical · Sep 15 Smartphone imaging shows 96% agreement with in-person cataract referrals in rural IndiaResearchers found 96% agreement between remote ophthalmologists reviewing smartphone images and in-person doctors for ca…
aip.org · Sep 15 Engineered heart tissue reveals fibroblast-cardiomyocyte crosstalk in hypertrophic cardiomyopathyResearchers using engineered micro-heart tissue discovered that communication between fibroblasts and cardiomyocytes is …
The Guardian · Sep 15 DRC Ebola outbreak peaks as daily cases decline from 120 to 80DRC authorities announce the Bundibugyo Ebola outbreak has peaked with daily cases dropping from 120 to 80, though nearl…
Viés e Enquadramento
Não há dados de análise detalhada para esta lente. Tente executar as lentes novamente no painel de administração.
Impacto Geopolítico
This is a biomedical research article about cancer immunology, not a geopolitical event. No international implications exist.
Lente Econômica
Research showing chronic interferon can paradoxically suppress anti-tumor immunity may accelerate development of immunotherapy treatments, potentially expanding the biotech and pharmaceutical markets.
Consumers may benefit from improved cancer immunotherapy treatments in 5-10 years, though near-term costs for clinical trials and new drug development may increase healthcare expenses.
FDA may need to revise immunotherapy approval pathways; increased funding for cancer research likely; potential regulatory changes for interferon-based treatments and combination therapies.